Evidence map›Paper›PMID 36373096›Full record

ArticleiScience2022

Enhanced virulence and waning vaccine-elicited antibodies account for breakthrough infections caused by SARS-CoV-2 delta and beyond.

Hyung-Joon Kwon, Martina Kosikova, Weichun Tang, Uriel Ortega-Rodriguez, Peter Radvak, Ruoxuan Xiang, Kelly E Mercer, Levan Muskhelishvili, Kelly Davis, Jerrold M Ward and 12 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Viral syncytia evolve to resist interferon.Nature communications · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Identification of nurse shark VFASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2023
    Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 6 institutions in 1 country.

Hyung-Joon KwonLaboratory of Pediatric and Respiratory Viral Diseases, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Silver Spring, MD, USA.
Martina KosikovaLaboratory of Pediatric and Respiratory Viral Diseases, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Silver Spring, MD, USA.
Weichun TangLaboratory of Pediatric and Respiratory Viral Diseases, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Silver Spring, MD, USA.
Uriel Ortega-RodriguezLaboratory of Pediatric and Respiratory Viral Diseases, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Silver Spring, MD, USA.
Peter RadvakLaboratory of Pediatric and Respiratory Viral Diseases, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Silver Spring, MD, USA.
Ruoxuan XiangDivision of Biostatistics, Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Silver Spring, MD, USA.
Kelly E MercerBiomarkers and Alternative Models Branch, National Center for Toxicological Research, United States Food and Drug Administration, Jefferson, AR, USA.
Levan MuskhelishviliToxicologic Pathology Associates, Jefferson, AR, USA.
Kelly DavisToxicologic Pathology Associates, Jefferson, AR, USA.
Jerrold M WardGlobal VetPathology, Montgomery Village, MD, USA.
Ivan KosikLaboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Jaroslav HollyLaboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Insung KangLaboratory of Pediatric and Respiratory Viral Diseases, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Silver Spring, MD, USA.
Jonathan W YewdellLaboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Ewan P PlantLaboratory of Pediatric and Respiratory Viral Diseases, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Silver Spring, MD, USA.
Wilbur H ChenCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Mallory C ShriverCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Robin S BarnesCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Marcela F PasettiCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Bin ZhouCDC COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
David E WentworthCDC COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Hang XieLaboratory of Pediatric and Respiratory Viral Diseases, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Silver Spring, MD, USA.
Center for Biologics Evaluation and Research · USUniversity of Maryland, Baltimore · USNational Institutes of Health · USCenters for Disease Control and Prevention · USGlobal VetPathology · USNational Center for Toxicological Research · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Here we interrogate the factors responsible for SARS-CoV-2 breakthrough infections in a K18-hACE2 transgenic mouse model. We show that Delta and the closely related Kappa variant cause viral pneumonia and severe lung lesions in K18-hACE2 mice. Human COVID-19 mRNA post-vaccination sera after the 2

Indexed as

Immune responseImmunologyVirology

Identifiers

PMID36373096
PMCPMC9635945
OpenAlexW4308261363

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.